To the editor: Understanding of the tumor microenvironment has led to the development of novel agents for lymphoma, although few studies have combined these as a therapeutic strategy. We report unacceptable toxicity from such a biological triplet. Patients were treated in a multiarm phase 1 study
No takes yet. Share an insight, caveat, or question.
Cheah et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: